Omega Diagnostics appoints Jeremy Millard to its Board as Independent Director

– UK, Alva – Omega Diagnostics Group PLC (LON:ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, today announced the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process.

The Board consider Jeremy to be independent and it is anticipated that he will, in due course, be appointed to the Audit and Remuneration Committees of the Company.

Bill Rhodes, Interim Non-Executive Chairman of the Company said: “We are delighted to have Jeremy join the Omega Board. With his relevant financial experience, familiarity with AIM-listed companies and his energy and enthusiasm for Omega, we feel confident that his appointment will bring immediate value to our Board and the Company in general.”

About Jeremy Millard

Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.